Skip to main content
SpringerLink
Log in

Immuntherapie urologischer Tumoren — Nebenwirkungen und ihre Behandlung

  • Chapter
Uroonkologie

  • 18 Accesses

Zusammenfassung

Die Definition und Dokumentation von Nebenwirkungen ist nicht nur wesentlicher Bestandteil jeder klinischen Studie, sondern auch Voraussetzung für ihr frühzeitiges Erkennen und ihre Behandlung.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Abrams J, Rayner A, Wiernik P, Parkinson D (1989) High dose Interleukin-2 without lymphokine activated killer cells: inactive in advanced renal call cancer. Proc Am Soc Clin Oncol 30: 380

    Google Scholar 

  • Aso Y, Tazaki H, Umeda T, Marumo K (1991) Treatment of advanced renal cell carcinoma by systemic low-dose recombinant interleukin-2. In: Debruyne FMJ, Bukowski RM, Pontes JE, deMulder PHM (eds) Immunotherapy of renal cell carcinoma. Springer, Berlin Heidelberg New York Tokyo, pp 91–103

    Chapter  Google Scholar 

  • Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM (1988) Hypothyroidism after treatment with Interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318: 1557–1563

    Article  PubMed  CAS  Google Scholar 

  • Atzpodien J, Kirchner H (1990) Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin Wochenschr 68:1–11

    Article  PubMed  CAS  Google Scholar 

  • Atzpodien J, Körfer A, Kirchner H (1991) Interleukin-2 and interferon alpha in renal cell carcinoma: the European experience. The second international symposium: immunobiology of renal cell carcinoma. Oct 21 and 22, 1991. Cleveland, Ohio/USA

    Google Scholar 

  • Belldegrun A, Webb DE, Austin HA, Steinberg SM, White DE, Linehan WM, Rosenberg SA (1987) Effects of Interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 106:817–822

    PubMed  CAS  Google Scholar 

  • Braley-Mullen H, Johnson M, Sharp GC, Kyriakos M (1985) Induction of experimental autoimmune thyroiditis in mice with in vitro activated splenic T cells. Cell Immunol 93:132–143

    Article  PubMed  CAS  Google Scholar 

  • Bruns P (1888) Die Heilwirkung des Erysipels auf Geschwülste. Beitr Klin Chir 3:443–466

    Google Scholar 

  • Bukowski RM, Goodman P, Crawford ED, Sergi JS, Redman BG, Whitehead RP (1990) Phase II trial of high-dose intermittent Interleukin-2 in metastatic renal cell carcinoma: Southwest Oncology Group Study. Reports 82:143–146

    CAS  Google Scholar 

  • Busch (1868) Verhandlungen ärztlicher Gesellschaften. Berl Klin Wochenschr 12:137–138

    Google Scholar 

  • Buzaid AC, Robertone A, Kisala C, Salmon SE (1987) Phase II study of recombinant interferon alfa-2a (Roferon-A) in metastatic renal cell carcinoma. J Clin Oncol 5:1083–1089

    PubMed  CAS  Google Scholar 

  • Coley WB (1891) Contribution to the knowledge of sarcoma. Ann Surg 14:199–220

    Article  PubMed  CAS  Google Scholar 

  • Creagan ET, Kovach JS, Moertel CG, Frytak S, Kvols LK (1988) A phase I clinical trial of recombinant human tumor necrosis factor. Cancer 62:2467–2471

    Article  PubMed  CAS  Google Scholar 

  • DeKernion JB, Sarna G, Figlin R, Lindner A, Smith RB (1983) The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J Urol 130:1063–1066

    PubMed  CAS  Google Scholar 

  • Dinarello CA (1989) Interleukin-1 and its biologically related cytokines. Adv. Immunol 44:153–205

    Article  PubMed  CAS  Google Scholar 

  • Dutcher J (1991) Clinical results with high dose interleukin-2 in the United States. The second international symposium: immunobiology of renal cell carcinoma, October 21 and 22, Cleveland, Ohio/USA

    Google Scholar 

  • Fossa SD (1991) Further experience with high dose interferon alpha and prednisone in metastatic renal cell carcinoma. The second international symposium: immunobiology of renal cell carcinoma, Oct 21 and 22, Cleveland, Ohio/USA

    Google Scholar 

  • Galligioni E, Sorio R, Sacco C et al. (1991) Recombinant Interleukin-2 (rIL2) by continuous infusion in patients with advanced renal cell cancer. The second international symposium: immunobiology of renal cell carcinoma, Oct 21 and 22, Cleveland, OH, USA, p 135

    Google Scholar 

  • Herr HW, Pinsky CM, Whitmore WF, Sogani PC, Oettgen HF, Melamed MR (1986) Long-term effect of intravesical bacillus calmette-guerin on flat carcinoma in situ of the bladder. J Urol 135:265–267

    PubMed  CAS  Google Scholar 

  • Hermann F, Mertelsmann R (1989) Tumornekrosefaktor. Dtsch Med Wochenschr 114:312–316

    Article  Google Scholar 

  • Herrmann F (1990) Die Stellung der Interferone in der Zytokinkaskade. In: Niederle N, von Wussow P (Hrsg) Interferone — Präklinische und klinische Befunde. Springer, Berlin Heidelberg New York Tokyo, S 53–64

    Chapter  Google Scholar 

  • Huland E (1992) IL-2 Inhalation beim pulmonal metastasierten Nierenzell-Ca. Symposium: Immuntherapie in der Uro-Onkologie. 6.–8. Februar 1992, Essen

    Google Scholar 

  • Jacobs SJ, Sullivan LM, Salfi M, Grossberg H, Spiegel RJ, Leibowitz PJ, Oden EM, Kelsey DK, Treuhaft MW (1988) Minimal antigenicity of Intron A in human recipients demonstrated by three analytical methods. J Biol Response Mod 7:447–456

    PubMed  CAS  Google Scholar 

  • Jacobsen H (1990) Struktur und Wirkung von Interferonen. In: Niederle N, von Wussow P (Hrsg) Interferone — Präklinische und klinische Befunde. Springer, Berlin Heidelberg New York Tokyo, S 1–44

    Chapter  Google Scholar 

  • Jakubowski AA, Casper ES, Gabrilove JL, Templeton M-A, Sherwin SA, Oettgen HF (1989) Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer. J Clin Oncol 7:298–303

    PubMed  CAS  Google Scholar 

  • Khanna OMP, Son DL, Mazer H et al. (1990) Multicenter study of superficial bladder cancer treated with intravesical bacillus calmette-guerin or adriamycin. Urology 35:101–108

    Article  PubMed  CAS  Google Scholar 

  • Kirkwood JM, Harris JE, Vera R et al. (1985) A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res 45:863–871

    PubMed  CAS  Google Scholar 

  • Kragel AH, Travis MD, Feinberg L et al. (1990) Pathologic findings associated with Interleukin-2-based immunotherpy for cancer: A postmortem study of 19 patients. Hum Pathol 21:493–502

    Article  PubMed  CAS  Google Scholar 

  • Krown SE, Einzig Al, Abramson JA (1983) Treatment of advanced renal cell cancer with recombinant leukocyte alpha interferon. Proc Am Soc Clin Oncol 2:58

    Google Scholar 

  • Kummer G, Kloke O, Niederle N (1990) Interferonrezeptoren: Charakterisierung und mögliche klinische Bedeutung. In: Niederle N, von Wussow P (Hrsg) Interferone. Präklinische und klinische Befunde. Springer, Berlin Heidelberg New York Tokyo, S 65–78

    Chapter  Google Scholar 

  • Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG (1986) Complications of Bacillus Calmette Guérin immunotherapy in 1278 patients with bladder cancer. J Urol 135:272–274

    PubMed  CAS  Google Scholar 

  • Lamm DL, Steg A, Boccon-Gibod L et al. (1989) Complications of Bacillus Calmette-Guérin immunotherapy: review of 2602 patients and comparison of chemotherapy complication. In: Debruyne FMJ, Denis L, van der Meijden APM (eds) BCG in superficial bladder cancer. Riss, New York, PP 335–355

    Google Scholar 

  • Lee RE, Lotze MT, Skibber JM et al. (1989) Cardiorespiratory effects of immunotherapy with Interleukin-2. J Clin Oncol 7:7–20

    PubMed  CAS  Google Scholar 

  • Maase H von der, Geertsen P, Thatcher N et al. (1991) Recombinant interleukin-2 in metastatic renal all carcinoma — a European multicenter phase II study. Eur J Cancer 27:1583–1589

    Article  PubMed  Google Scholar 

  • Margolin KA, Rayner AA, Hawkins MJ et al. (1989) Interleukin-2 and lymphokineactivated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 7: 486–498

    PubMed  CAS  Google Scholar 

  • Marumo K, Murai M, Hayakawa M, Tazaki H (1984) Human lymphoblastoid interferon therapy for advanced renal cell carcinoma. Urology 6:567–571

    Article  Google Scholar 

  • Marumo K, Muraki J, Ueno M et al. (1989) Immunologic study of human recombinant Interleukin-2 (low-dose) in patients with advanced renal cell carcinoma. Urology 33:219–225

    Article  PubMed  CAS  Google Scholar 

  • Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116:180–183

    PubMed  CAS  Google Scholar 

  • Muss HB, Costanzi JJ, Leavitt R et al. (1987) Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol 5:286–291

    PubMed  CAS  Google Scholar 

  • Neidhart JA, Gagen MM, Young D, Tuttle R, Melink TJ, Ziccarrelli A, Kisner D (1984) Interferonalpha therapy of renal cancer. Cancer Res 44:4140–4143

    PubMed  CAS  Google Scholar 

  • O’Garra A (1989a) Interleukins and the immune system 1. Lancet 1:943–946

    PubMed  Google Scholar 

  • O’Garra A (1989b) Interleukins and the immune system 2. Lancet 1:1003–1005

    Article  PubMed  Google Scholar 

  • Orihuela E, Herr HW, Pinsky CM, Whitmore WF (1987) Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer 60:326–333

    Article  PubMed  CAS  Google Scholar 

  • Puri RK, Travis WD, Rosenberg SA (1989) Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin-i alpha in vivo. Cancer Res 49: 969–976

    PubMed  CAS  Google Scholar 

  • Quesada JR, Swanson DA, Trindade A, Gutterman JU (1983) Renal cell carcinoma: anti tumor effects of leukocyte interferon. Cancer Res 43:940–943

    PubMed  CAS  Google Scholar 

  • Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU (1985a) Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 3:1522–1528

    PubMed  CAS  Google Scholar 

  • Quesada JR, Swanson DA, Gutterman JU (1985b) Phase II study of interferon alpha in metastatic renal cell carcinoma: a progress report. J Clin Oncol 3:1086–1092

    PubMed  CAS  Google Scholar 

  • Reid I, McDevitt SJ, Emmons MR, Tanner WA, Monson JRT (1991) Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha. Cancer 64: 915–918

    Article  CAS  Google Scholar 

  • Richards JM, Barker E, Latta J, Ramming K, Vogelzang NJ (1988) Phase I study of weekly 24-hours infusions of recombinant human interleukin-2. J Natl Cancer Inst 80:1325–1328

    Article  PubMed  CAS  Google Scholar 

  • Rombis V, Gaganakis J, Salfigides G, Hafalamfous S, Anastasiadis G (1989) The treatment of metastatic renal cell carcinoma with alpha-interferon. J 16th Int Cong Chemotherapy, p 14

    Google Scholar 

  • Rosenberg SA, Lotze MT, Muul LM (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg SA, Lotze MT, Yang JC, Uebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose Interleukin-2 in the treatment of 652 patients. Ann Surg: 474–485

    Google Scholar 

  • Rosenthal FM, Lindemann A, Herrmann F, Mertelsmann R (1991) Zytokine in der Tumortherapie. Die Gelben Hefte 31:51–60

    Google Scholar 

  • Samlowski WE, Ward JH, Craven CM, Freedman RA (1989) Severe myocarditis following high-dose Interleukin-2 administration. Arch Pathol Lab Med 113:838–841

    PubMed  CAS  Google Scholar 

  • Schwarz JA (1990) Vorschlag für einen Standardprüfplan und eine Patienteneinverständniserklärung. In: Witte PU, Schenk J, Schwarz JA, Kori-Lindner C (Hrsg) Ordnungsgemäße klinische Prüfung. Habrich, Fürth, S 11–50

    Google Scholar 

  • Shinka T, Hirano Y, Uekado I, Kyoku I, Aoshi H, Ohkawa T (1989) Intravesical bacillus calmette-guerin treatment for superficial bladder tumours. Br J Urol 63:610–615

    Article  PubMed  CAS  Google Scholar 

  • Sosman JA, Kohler PC, Hank J, Moore KH, Bechhofer R, Storer B, Sondel PM (1988) Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity. J Natl Cancer Inst 80:60–63

    Article  PubMed  CAS  Google Scholar 

  • Steineck G, Strander H, Carbin BE et al. (1989) Recombinant leukocyte interferon alpha-2A and medroxyprogesterone in advanced renal cell carcinoma. Acta Oncol 29:155–162

    Article  Google Scholar 

  • Steis RG, Smith JW, Urba WJ et al. (1988) Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing antunterferon antibodies. N Engl J Med 318:1409–1413

    Article  PubMed  CAS  Google Scholar 

  • Umeda T, Niijima T (1986) Phase II study of alpha interferon on renal cell carcinoma. Cancer 58: 1231–1235

    Article  PubMed  CAS  Google Scholar 

  • Vetto JT, Papa MZ, Lotze MT, Chang AE, Rosenberg SA (1987) Reduction of toxicity of Interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J Clin Oncol 5:496–503

    PubMed  CAS  Google Scholar 

  • Vugrin D, Hood L, Taylor W, Laszlo J (1985) Phase II study of human lymphoblastoid interferon in patients with advanced renal carcinoma. Cancer Treat Rep 69:817–820

    PubMed  CAS  Google Scholar 

  • Whitehead RP, Ward D, Hemingway L, Hemstreet GP, Bradley E, Konrad M (1990) Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma. Cancer Res 50:6708–6715

    PubMed  CAS  Google Scholar 

  • Wiedenmann B, Reichard P, Räth U et al. (1989) Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas. J Cancer Res Clin Oncol 115:189–192

    Article  PubMed  CAS  Google Scholar 

  • Wong GG, Witek-Giannotti JS, Temple TA (1988) Stimulation of murine hemopoietic colony formation by human IL-6. Immunol 140:3040–3044

    CAS  Google Scholar 

  • Wussow P von, Jakschies D (1990) Interferon-Antikörper — Phantasie oder Faktum. In: Niederle N, von Wussow P (Hrsg) Interferone. Präklinische und klinische Befunde. Springer, Berlin Heidelberg New York Tokyo, S 79–91

    Chapter  Google Scholar 

Download references

Authors
  1. T. Ebert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Vögeli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. J. Schmitz-Dräger
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Urologische Klinik und Poliklinik, Medizinische Einrichtungen der Universität-GHS Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Herbert Rübben (Direktor der Urologischen Klinik und Poliklinik) (Direktor der Urologischen Klinik und Poliklinik)

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Ebert, T., Vögeli, T., Schmitz-Dräger, B.J. (1997). Immuntherapie urologischer Tumoren — Nebenwirkungen und ihre Behandlung. In: Rübben, H. (eds) Uroonkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10731-7_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10731-7_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-10732-4

  • Online ISBN: 978-3-662-10731-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation